| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
30,615 |
28,209 |
$1.77M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,493 |
13,391 |
$1.12M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
9,631 |
9,111 |
$1.06M |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,701 |
3,500 |
$357K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,078 |
1,018 |
$132K |
| 80305 |
|
12,055 |
11,406 |
$88K |
| 20611 |
|
1,061 |
964 |
$74K |
| 64493 |
|
415 |
392 |
$53K |
| 64483 |
|
274 |
262 |
$49K |
| 93922 |
|
502 |
487 |
$38K |
| 95923 |
|
383 |
371 |
$29K |
| 95921 |
|
381 |
369 |
$20K |
| 64494 |
|
371 |
350 |
$15K |
| 64495 |
|
332 |
313 |
$14K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
2,206 |
2,031 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
322 |
292 |
$6K |
| 64484 |
|
109 |
101 |
$5K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
165 |
61 |
$5K |
| 20610 |
|
73 |
68 |
$4K |
| 99439 |
|
556 |
556 |
$4K |
| 96132 |
|
82 |
80 |
$4K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
117 |
56 |
$4K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
17 |
17 |
$2K |
| A4657 |
Syringe, with or without needle, each |
2,798 |
2,514 |
$2K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
111 |
55 |
$2K |
| 62323 |
|
13 |
13 |
$2K |
| 97750 |
|
89 |
79 |
$2K |
| A6220 |
Gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing |
3,039 |
2,778 |
$2K |
| 95911 |
|
13 |
13 |
$2K |
| 96138 |
|
35 |
35 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
59 |
39 |
$1K |
| 97035 |
|
110 |
69 |
$879.65 |
| 96004 |
|
15 |
15 |
$834.08 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
967 |
928 |
$819.73 |
| 95886 |
|
15 |
15 |
$690.64 |
| A4215 |
Needle, sterile, any size, each |
3,583 |
3,247 |
$485.16 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
867 |
776 |
$346.90 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,501 |
1,408 |
$237.28 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,797 |
1,513 |
$207.89 |
| 96127 |
|
21 |
18 |
$139.14 |
| 99490 |
Ccm add 20min |
556 |
556 |
$45.60 |
| 96130 |
|
37 |
37 |
$31.64 |
| 83992 |
|
51 |
49 |
$15.90 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
2,695 |
2,449 |
$15.10 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
78 |
77 |
$2.39 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
80 |
79 |
$2.24 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
78 |
77 |
$0.51 |
| 99487 |
Ccm add 20min |
18 |
18 |
$0.00 |
| 99457 |
|
96 |
96 |
$0.00 |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
35 |
35 |
$0.00 |
| 99489 |
Ccm add 20min |
18 |
18 |
$0.00 |
| 99458 |
|
27 |
27 |
$0.00 |